世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
鎌状赤血球症治療薬市場。世界の業界動向、シェア、サイズ、成長、機会、および2021-2026年の予測Sickle Cell Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global sickle cell disease treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 11.8% during 2021-2026. Sickle cell... もっと見る
サマリーThe global sickle cell disease treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 11.8% during 2021-2026.Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. It leads to many complications, such as acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). At present, blood and bone marrow transplant is commonly suggested by doctors for treating SCD. It involves replacing affected bone marrow with a healthy substitute received from a donor. Other effective treatments, such as medications and blood transfusions, are also being utilized as they can reduce specific symptoms and prolong the life of patients. A considerable increase in the number of individuals suffering from SCD represents one of the significant factors influencing the demand for new medications that can treat the condition effectively. As a result, the health regulatory authorities of numerous countries are focusing on fast-track approval of new treatment methods. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. Additionally, government authorities are supporting research and development (R&D) activities to encourage researchers and pharmaceutical companies to develop novel treatments. For instance, researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the US are working on genetic therapies that can restore a missing gene or add a new DNA strain to improve the functioning of cells. These innovations, along with the rising disposable incomes and the growing awareness among individuals about the available healthcare services, are anticipated to contribute to market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global sickle cell disease treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type and end user. Breakup by Treatment Type: Blood Transfusion Pharmacotherapy Bone Marrow Transplant Breakup by End User: Hospitals Diagnostic centers Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics. Key Questions Answered in This Report: How has the global sickle cell disease treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global sickle cell disease treatment market? What are the key regional markets? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global sickle cell disease treatment market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Sickle Cell Disease Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Blood Transfusion 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Pharmacotherapy 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Bone Marrow Transplant 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by End User 7.1 Hospitals 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Diagnostic centers 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 AstraZeneca Plc 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Baxter International Inc. 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 bluebird bio Inc. 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 Financials 13.3.3.4 SWOT Analysis 13.3.4 Bristol-Myers Squibb Company 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 CRISPR Therapeutics 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.6 Emmaus Medical Inc. 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.7 Global Blood Therapeutics Inc. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.8 GlycoMimetics Inc. 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.9 Novartis AG 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 Pfizer Inc. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis 13.3.11 Sangamo Therapeutics 13.3.11.1 Company Overview 13.3.11.2 Product Portfolio 13.3.11.3 Financials 13.3.11.4 SWOT Analysis
SummaryThe global sickle cell disease treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 11.8% during 2021-2026.Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. It leads to many complications, such as acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). At present, blood and bone marrow transplant is commonly suggested by doctors for treating SCD. It involves replacing affected bone marrow with a healthy substitute received from a donor. Other effective treatments, such as medications and blood transfusions, are also being utilized as they can reduce specific symptoms and prolong the life of patients. A considerable increase in the number of individuals suffering from SCD represents one of the significant factors influencing the demand for new medications that can treat the condition effectively. As a result, the health regulatory authorities of numerous countries are focusing on fast-track approval of new treatment methods. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. Additionally, government authorities are supporting research and development (R&D) activities to encourage researchers and pharmaceutical companies to develop novel treatments. For instance, researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the US are working on genetic therapies that can restore a missing gene or add a new DNA strain to improve the functioning of cells. These innovations, along with the rising disposable incomes and the growing awareness among individuals about the available healthcare services, are anticipated to contribute to market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global sickle cell disease treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type and end user. Breakup by Treatment Type: Blood Transfusion Pharmacotherapy Bone Marrow Transplant Breakup by End User: Hospitals Diagnostic centers Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics. Key Questions Answered in This Report: How has the global sickle cell disease treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global sickle cell disease treatment market? What are the key regional markets? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global sickle cell disease treatment market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Sickle Cell Disease Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Blood Transfusion 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Pharmacotherapy 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Bone Marrow Transplant 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by End User 7.1 Hospitals 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Diagnostic centers 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 AstraZeneca Plc 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Baxter International Inc. 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 bluebird bio Inc. 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 Financials 13.3.3.4 SWOT Analysis 13.3.4 Bristol-Myers Squibb Company 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 CRISPR Therapeutics 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.6 Emmaus Medical Inc. 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.7 Global Blood Therapeutics Inc. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.8 GlycoMimetics Inc. 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.9 Novartis AG 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 Pfizer Inc. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis 13.3.11 Sangamo Therapeutics 13.3.11.1 Company Overview 13.3.11.2 Product Portfolio 13.3.11.3 Financials 13.3.11.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
IMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポートよくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/18 10:26 151.13 円 164.11 円 199.39 円 |
